Opisthorchiasis medical therapy: Difference between revisions
Created page with "__NOTOC__ {{Opisthorchiasis}} Please help WikiDoc by adding content here. It's easy! Click here to learn about editing. ==References== {{Reflis..." |
m Changes made per Mahshid's request |
||
| (2 intermediate revisions by one other user not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Opisthorchiasis}} | {{Opisthorchiasis}} | ||
{{CMG}} | |||
==Medical Therapy== | |||
There was unsuccessful use of [[chloroquine]] for opisthorchiasis treatment in 1951-1968. | |||
Thus, currently, the control of opisthorchiasis relies predominantly on [[anthelmintic]] treatment with [[praziquantel]]. The single dose of praziquantel of 40 mg/kg is effective against opisthorchiasis and also against [[schistosomiasis]]. A randomised-controlled trial published in 2011 showed that the broad-spectrum anti-helminthic, tribendimidine, appears to be at least as efficacious as praziquantel. | |||
[[Artemisinin]] was also found to have [[anthelmintic]] activity against ''Opisthorchis viverrini''. | |||
Despite the efficacy of this compound, the lack of an acquired immunity to infection predisposes humans to reinfections in endemic regions. In addition, under experimental conditions, the short-term treatment of ''Opisthorchis viverrini''-infected [[hamster]]s with praziquantel (400 mg per kg of live weight) has been shown to induce a dispersion of parasite antigens, resulting in adverse immunopathological changes as a result of oxidative and nitrative stresses following re-infection with ''Opisthorchis viverrini'', a process which has been proposed to initiate and/or promote the development of cholangiocarcinoma in humans. | |||
Given the current reliance on a single trematocidal drug against ''Opisthorchis viverrini'', there is substantial merit in searching for new intervention methods, built on a detailed understanding of the interplay between the parasites and their hosts as well as the biology of the parasites themselves at the molecular level. Furthermore, the characterization of the genes expressed in these parasites should assist in elucidating the molecular mechanisms by which opisthorchiasis initiate and enhance the development of cholangiocarcinoma. | |||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
[[Category:Needs | [[Category:Needs overview]] | ||
[[Category:Disease]] | [[Category:Disease]] | ||
[[Category:Helminthiases]] | [[Category:Helminthiases]] | ||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} | ||
Latest revision as of 18:32, 18 September 2017
|
Opisthorchiasis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Opisthorchiasis medical therapy On the Web |
|
American Roentgen Ray Society Images of Opisthorchiasis medical therapy |
|
Risk calculators and risk factors for Opisthorchiasis medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Medical Therapy
There was unsuccessful use of chloroquine for opisthorchiasis treatment in 1951-1968. Thus, currently, the control of opisthorchiasis relies predominantly on anthelmintic treatment with praziquantel. The single dose of praziquantel of 40 mg/kg is effective against opisthorchiasis and also against schistosomiasis. A randomised-controlled trial published in 2011 showed that the broad-spectrum anti-helminthic, tribendimidine, appears to be at least as efficacious as praziquantel.
Artemisinin was also found to have anthelmintic activity against Opisthorchis viverrini.
Despite the efficacy of this compound, the lack of an acquired immunity to infection predisposes humans to reinfections in endemic regions. In addition, under experimental conditions, the short-term treatment of Opisthorchis viverrini-infected hamsters with praziquantel (400 mg per kg of live weight) has been shown to induce a dispersion of parasite antigens, resulting in adverse immunopathological changes as a result of oxidative and nitrative stresses following re-infection with Opisthorchis viverrini, a process which has been proposed to initiate and/or promote the development of cholangiocarcinoma in humans.
Given the current reliance on a single trematocidal drug against Opisthorchis viverrini, there is substantial merit in searching for new intervention methods, built on a detailed understanding of the interplay between the parasites and their hosts as well as the biology of the parasites themselves at the molecular level. Furthermore, the characterization of the genes expressed in these parasites should assist in elucidating the molecular mechanisms by which opisthorchiasis initiate and enhance the development of cholangiocarcinoma.